Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Ian Mortimer and CFO Sherry Aulin will speak at three upcoming virtual investor conferences. The Guggenheim 3rd Annual Neuro/Immunology Conference will take place on November 15, 2021, featuring one-on-one meetings. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, including a fireside chat at 1:20 pm ET. Lastly, the Jefferies London Healthcare Conference is set for November 18, 2021, with an on-demand fireside chat starting at 8:00 am GMT. For updates, visit investor.xenon-pharma.com.

BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will participate virtually in the following investor conferences:

• Guggenheim 3rd Annual Neuro/Immunology Conference on Monday, November 15, 2021 (one-on-one meetings only)
• Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, with fireside chat presentation at 1:20 pm ET
• Jefferies London Healthcare Conference on Thursday, November 18, 2021, with on-demand streaming of fireside chat presentation beginning at 8:00 am GMT / 3:00 am ET
  

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

FAQ

What investor conferences will Xenon Pharmaceuticals participate in November 2021?

Xenon Pharmaceuticals will participate in the Guggenheim 3rd Annual Neuro/Immunology Conference on November 15, Stifel 2021 Virtual Healthcare Conference on November 17, and Jefferies London Healthcare Conference on November 18, 2021.

What is the schedule for Xenon Pharmaceuticals' virtual presentations?

The schedule is as follows: November 15, 2021 - Guggenheim Conference (one-on-one meetings), November 17, 2021 - Stifel Conference at 1:20 pm ET, November 18, 2021 - Jefferies Conference with on-demand streaming available from 8:00 am GMT.

Where can I find more information about Xenon Pharmaceuticals' conferences?

For more information about Xenon Pharmaceuticals' investor conferences and webcasts, visit the 'Investors' section on their website at investor.xenon-pharma.com.

What is the focus of Xenon Pharmaceuticals' research?

Xenon Pharmaceuticals is focused on developing innovative therapeutics to treat neurological disorders, with a strong emphasis on epilepsy.